Exane BNP Paribas Upgrades Eramet to Outperform

Exane BNP Paribas analyst Sylvain Brunet upgrades Eramet (OTC:ERMAY) from Neutral to Outperform.

byBenzinga Newsdesk

October 6, 2021

1 minute read

Exane BNP Paribas analyst Sylvain Brunet upgrades Eramet (OTC:ERMAY) from Neutral to Outperform.

New York Public Service Commission Approves Exelon Separation

By Benzinga Newsdesk

Today, 10:43 PM

Exelon Corp. (NASDAQ:EXC) announced today that the New York State Public Service Commission has approved a unanimous settlement agreement that allows Exelon to move forward with its plan to separate into two companies in the first quarter of 2022.

EXC

Raymond James Initiates Coverage On U.S. Century Bank with Outperform Rating, Announces Price Target of $13

By Benzinga Newsdesk

Today, 10:43 PM

Raymond James analyst Michael Rose initiates coverage on U.S. Century Bank (NASDAQ:USCB) with a Outperform rating and announces Price Target of $13.

USCB

Pfizer, Arvinas Report PROTAC Protein Degrader ARV-471 Continues To Show Clinical Benefit Rate In Patients With Locally Advanced, Metastatic ER-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

By Benzinga Newsdesk

Today, 10:43 PM

– ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium – – ARV-471 is expected

ARVN